PTPLB catalyzes the dehydration of 3-hydroxyacyl-CoA intermediates during fatty acid elongation. This step is critical for converting saturated, monounsaturated, and polyunsaturated fatty acids (FAs) into very long-chain FAs (VLCFAs), which are essential for membrane lipids, cholesterol esters, and sphingolipids .
Studies in Hacd1 knockout (KO) mice and human HAP1 cells reveal:
Yeast Assays: Overexpression of PTPLB in yeast rescues FA elongation defects, confirming its role in both saturated and unsaturated pathways .
Cellular Disruption: CRISPR-mediated knockout of HACD2 in human cells significantly reduces elongation of C18 and longer FAs, while HACD1 KO has minimal impact .
PTPLB’s recombinant form is widely used to study:
Lipid Pathway Dynamics: Elucidating the interplay between HACD1 and PTPLB in VLCFA synthesis .
Disease Modeling: Investigating myopathies linked to HACD1 mutations, where PTPLB compensatory activity may influence disease progression .
Therapeutic Targeting: Exploring inhibitors or modulators of PTPLB for lipid-related disorders (e.g., sphingolipidoses) .